David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), sat down with Proactive London's Andrew Scott after taking on the role back in August.
Silence expects to kick off its first-in-human clinical trial in the second half of next year.
The company specialises in RNA interference – a type of treatment which works by suppressing, or ‘silencing’, genes that are thought to cause diseases.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE